Jujuboside A (Synonyms:酸枣仁皂苷 A)
目录号 : KM18739 CAS No. : 55466-04-1 纯度 : 98%

Jujuboside A是从中药酸枣仁中提取的糖苷,可以用于失眠和焦虑症状的相关研究。

规格 价格 是否有货 数量
5mg
In-stock
10mg
In-stock
25mg
In-stock
50mg
In-stock
100mg
In-stock
200mg 询价 In-stock
500mg 询价 In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

Jujuboside A is a glycoside extracted from Semen Ziziphi Spinosae, a Chinese herbal medicine used to treat insomnia and anxiety.

体外研究

Jujuboside A at the low dose of 41 μM (about 0.05 g/L) induces significant increase of GABA(A) receptor α1, α5, β2 subunit mRNAs in both 24 and 72h treatments. Jujuboside A at the high dose of 82 μM (about 0.1 g/L) significantly increases GABA(A) receptor α1, α5 subunit mRNA levels and decreases β2 subunit mRNA level at 24h treatment, and decreases GABA(A) receptor subunit α1, β2 mRNAs expression at 72h treatment. Jujuboside A pretreatment could reverse the reduction of cell viability and better the injury of H9C2 cells induced by ISO. Jujuboside A could accelerate the phosphorylation of PI3K, Akt, and mTOR. Jujuboside A could significantly decrease the ratio of microtubule-associated protein LC3-II/I in H9C2 cells.

体内研究

During daytime (9:00-15:00), jujubosides significantly increases the total sleep and rapid eye movement (REM) sleep without significant influence on non-REM (NREM) sleep. During nighttime (21:00-3:00), jujubosides significantly increases the total sleep and NREM sleep especially the light sleep while shows no significant effect on REM sleep and slow wave sleep (SWS). Intracerebroventricular treatment with Jujuboside A significantly mitigates learning and memory impairment in mice induced by Aβ1–42 as measured by the Y-maze, active avoidance and Morris water maze. Intracerebroventricular treatment with Jujuboside A reduces the level of Aβ1–42 in hippocampus, significantly inhibits the activities of acetylcholinesterase (AChE) and NO, and decreases the amount of the increased malondialdehyde (MDA) in the hippocampus and cerebral cortex of mice treated with intracerebroventricular injection of Aβ1–42.

分子式
C58H94O26
分子量
1207.35
CAS号
55466-04-1
中文名称
酸枣仁皂苷 A
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (82.83 mM; Need ultrasonic)

H2O : 50 mg/mL (41.41 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.8283 mL 4.1413 mL 8.2826 mL
5 mM 0.1657 mL 0.8283 mL 1.6565 mL
10 mM 0.0828 mL 0.4141 mL 0.8283 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.07 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.07 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.07 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

科研文献
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
在线客服
咨询热线
400-881-9290
关注微信公众号